Management of Postthrombolysis Hemorrhagic and Orolingual Angioedema Complications.
Intravenous recombinant tissue plasminogen activator was first approved for the treatment of acute ischemic stroke in the United States in 1996. Thrombolytic therapy has been proven to be effective in acute ischemic stroke treatment and shown to improve long-term functional outcomes. Its use is associated with an increased risk of symptomatic intracerebral hemorrhage as well as orolingual angioedema. Our goal is to outline the management strategies for these postthrombolysis complications.
Department of Neurology, Division of Cerebrovascular Diseases, Mayo Clinic, Phoenix, AZ, USA.
Cumara B
CB
O'Carroll
Department of Neurology, Division of Cerebrovascular Diseases, Mayo Clinic, Phoenix, AZ, USA.
Maria I
MI
Aguilar
cerebrovascular disorders; clinical specialty; intracranial hemorrhages; neurohospitalist; stroke